Login
$ACRS
$3.66 +$0.05 (1.52%) After hours

$ACRS SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 -

27 Oct 2026 8-K: Entry into a Material Definitive Agreement

Pre-Funded Warrants to Purchase 6,500,000 Shares of Common Stock

27 Oct 2026 424B5
27 Oct 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION October 27, 2026 ATI-052 Phase 1b Primary Analysis Results Atopic Dermatitis and Asthma

21 Sep 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G/A
06 Aug 2026 8-K: Entry into a Material Definitive Agreement

Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and Leerink Partners LLC and Cantor Fitzgerald & Co., as sales agents and/or principals (collectively the “Agents,” and each individually an “Agent”), are parties to tha...

06 Aug 2026 S-3ASR
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing -

04 Aug 2026 Form 4: Kolbeck Roland Wilhelm, Chief Scientific Officer

Received 36,375 shares by exercise or conversion · Gave up 12,385 shares to cover exercise price or tax ($64.4K)

08 Jun 2026 Form 4: Mehra Anand, Director

Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion

08 Jun 2026 Form 4: Schiff Andrew N, Director

Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion

08 Jun 2026 Form 4: Humphries William D., Director

Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion

08 Jun 2026 Form 4: Molineaux Christopher P., Director

Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion

08 Jun 2026 Form 4: Milano Vincent, Director

Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion

08 Jun 2026 Form 4: Gowen Maxine, Director

Granted 42,350 Stock Option (Right to Buy) · Granted 10,987 Restricted Stock Units · Received 11,580 shares by exercise or conversion

04 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 4, 2026, Aclaris Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered three proposals, each of which is described in more detail in the Company’s defi...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support